L-5103 Lepetit en es it fr

L-5103 Lepetit Brand names, L-5103 Lepetit Analogs

L-5103 Lepetit Brand Names Mixture

  • Rifater (Isoniazid + Pyrazinaamide + Rifampin)
  • Rifamate (Rifampin + Isoniazid)

L-5103 Lepetit Chemical_Formula


L-5103 Lepetit RX_link


L-5103 Lepetit fda sheet

L-5103_Lepetit FDA

L-5103 Lepetit msds (material safety sheet)

L-5103_Lepetit MSDS

L-5103 Lepetit Synthesis Reference

No information avaliable

L-5103 Lepetit Molecular Weight

822.94 g/mol

L-5103 Lepetit Melting Point

183 oC

L-5103 Lepetit H2O Solubility

1.4 mg/mL

L-5103 Lepetit State


L-5103 Lepetit LogP


L-5103 Lepetit Dosage Forms


L-5103 Lepetit Indication

For the treatment of Tuberculosis and Tuberculosis-related mycobacterial infections.

L-5103 Lepetit Pharmacology

Rifampin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifampin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.

L-5103 Lepetit Absorption

Well absorbed from gastrointestinal tract.

L-5103 Lepetit side effects and Toxicity

LD50=1570 mg/kg (rat), chronic exposure may cause nausea and vomiting and unconsciousness

L-5103 Lepetit Patient Information

The patient should be told that rifampin may produce a reddish coloration of the urine, sweat, sputum, and tears, and the patient should be forewarned of this. Soft contact lenses may be permanently stained. The patients should be advised that the reliability of oral or other systemic hormonal contraceptives may be affected; consideration should be given to using alternative contraceptive measures. Patients should be instructed to take rifampin either 1 hour before or 2 hours after a meal with a full glass of water. Patients should be instructed to notify their physicians promptly if they experience any of the following: fever, loss of appetite, malaise, nausea and vomiting, darkened urine, yellowish discoloration of the skin and eyes, and pain or swelling of the joints. Compliance with the full course of therapy must be emphasized, and the importance of not missing any doses must be stressed.

L-5103 Lepetit Organisms Affected

Mycobacteria and a variety of other gram negative and gram postivie bacteria